Synapse - Works

Results (5612)

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours

Meeting Abstract

Schram, A. M.; Drilon, A.; Macarulla Mercade, T.; O'Reilly, E. M.; Rodon, J. A.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C. H.; Lam, Y. C. J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)

Meeting Abstract

Rischin, D.; Lim, A. M.; Schmults, C. D.; Khushalani, N. I.; Hughes, B. G.; Schadendorf, D.; Dunn, L. A.; Chang, A. L. S.; Hauschild, A.; Ulrich, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

Meeting Abstract

Meyer, T.; Kelley, R. K.; Mangeshkar, M.; Cheng, A. L.; El-Khoueiry, A. B.; Abou-Alfa, G. K.
Annals of Oncology (2019)

Fulltext@MSK | Save

Impact of the IDEA study on clinical practice for stage III colon cancer patients: A French GERCOR - FFCD - GI UNICANCER national survey

Meeting Abstract

Ouali, K.; Cohen, R.; Turpin, A.; Neuzillet, C.; Rousseau, B.; Garcia-Larnicol, M. L.; Tournigand, C.; Samalin, E.; Taieb, J.; André, T.
Annals of Oncology (2019)

Fulltext@MSK | Save

cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)

Meeting Abstract

Pal, S. K.; Bajorin, D. F.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; Burris, H. A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer

Meeting Abstract

Moukarzel, L. A.; Stylianou, A.; Wu, M.; Nobre, S. P.; Abu-Rustum, N. R.; Broach, V.; Giri, D. D.; Iyengar, N. M.; Weigelt, B.; Makker, V.
Annals of Oncology (2019)

Fulltext@MSK | Save

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Meeting Abstract

Moore, K.; Oza, A.; Colombo, N.; Oaknin, A.; Scambia, G.; Lorusso, D.; Farias-Eisner, R.; Banerjee, S.; Murphy, C.; Tanyi, J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy

Meeting Abstract

McArthur, H. L.; Comen, E. A.; Bryce, Y.; Solomon, S. B.; Leal, J. H. S.; Rodine, M.; Abaya, C. D.; Patil, S.; Page, D. B.; Norton, L.
Annals of Oncology (2019)

Fulltext@MSK | Save

Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment

Meeting Abstract

Ledermann, J. A.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1

Meeting Abstract

McGregor, B. A.; O'Donnell, P. H.; Balar, A.; Petrylak, D. P.; Rosenberg, J. E.; Yu, E.; Quinn, D. I.; Shah, S. N.; Pinelli, J.; Hepp, Z.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save